Zymeworks Inc Quick Ratio (ZYME) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Zymeworks Inc   (NASDAQ: ZYME)

Zymeworks Inc 's Quick Ratio

ZYME's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 5.73 above Zymeworks Inc average.

Within Major Pharmaceutical Preparations industry 169 other companies have achieved higher Quick Ratio than Zymeworks Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 505 to 737.

Explain Quick Ratio?
How much Cash & cash equivalents ZYME´s has?
What are ZYME´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ZYME Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 22.7 % -45.24 % -52.07 % -49.89 % -29.63 %
Y / Y Cash & cash equivalent Change 175.51 % 220.56 % -37.74 % -47.01 % 38.46 %
Quick Ratio MRQ 5.73 6.85 0.97 1.54 2.55
ZYME's Total Ranking # 737 # 505 # 1700 # 1160 # 814
Seq. Current Liabilities Change 32.52 % -15.76 % 0.65 % 9.2 % -40.86 %
Seq. Cash & cash equivalent Change 10.81 % 493.54 % -36.52 % -34.01 % 28.93 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 170
Healthcare Sector # 275
Overall Market # 737


Quick Ratio Statistics
High Average Low
13.95 5.09 0.75
(Sep 30 2018)   (Dec 31 2024)




Financial Statements
Zymeworks Inc 's Current Liabilities $ 47 Millions Visit ZYME's Balance sheet
Zymeworks Inc 's Cash & cash equivalent $ 271 Millions Visit ZYME's Balance sheet
Source of ZYME's Sales Visit ZYME's Sales by Geography


Cumulative Zymeworks Inc 's Quick Ratio

ZYME's Quick Ratio for the trailling 12 Months

ZYME Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -39.36 % -45.72 % -33.77 % -7.72 % 13.76 %
Y / Y Cash & cash equivalent TTM Growth 71.11 % 33.64 % -25.06 % -55.25 % -57.58 %
Quick Ratio TTM 3.71 2.83 1.49 1.31 1.32
Total Ranking TTM # 3712 # 3036 # 2909 # 2970 # 2991
Seq. Current Liabilities TTM Growth 5.51 % -15.67 % -19.65 % -15.18 % -5.55 %
Seq. Cash & cash equivalent TTM Growth 38.45 % 59.93 % -8.17 % -15.85 % 8.13 %

Quick ratio ranking by company, industry and sector >> Back to ZYME Financial Strength Comparisons >> Go to Compare ZYME Quick Ratio to its Competitors

On the trailing twelve months basis ZYME Cash & cash equivalent more than doubled by 175.51 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Zymeworks Inc 's Quick Ratio to 3.71, above ZYME average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 427 other companies have achieved higher Quick Ratio than Zymeworks Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3036 to 3712.

Explain Quick Ratio?
How much Cash & cash equivalents ZYME´s has?
What are ZYME´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 428
Healthcare Sector # 871
Within the Market # 3712


trailing twelve months Quick Ratio Statistics
High Average Low
4.15 2.52 1.15
(Sep 30 2019)   (Mar 31 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Corvus Pharmaceuticals Inc   15.74 $ 215.200  Millions$ 13.672  Millions
Telomir Pharmaceuticals Inc   15.55 $ 5.170  Millions$ 0.332  Millions
Rapport Therapeutics Inc   15.34 $ 436.077  Millions$ 28.424  Millions
Lb Pharmaceuticals Inc  15.32 $ 369.576  Millions$ 24.128  Millions
Anixa Biosciences Inc   15.09 $ 26.330  Millions$ 1.745  Millions
Siga Technologies Inc  14.99 $ 117.584  Millions$ 7.845  Millions
Vyne Therapeutics Inc   14.87 $ 22.925  Millions$ 1.542  Millions
Alto Neuroscience Inc   14.64 $ 243.733  Millions$ 16.652  Millions
Tenax Therapeutics Inc   14.62 $ 118.000  Millions$ 8.073  Millions
Jade Biosciences Inc   14.61 $ 461.205  Millions$ 31.570  Millions
Immunome Inc   14.56 $ 519.996  Millions$ 35.713  Millions
Sensei Biotherapeutics Inc   14.54 $ 186.441  Millions$ 12.824  Millions
Cytokinetics Incorporated  14.39 $ 2,610.415  Millions$ 181.429  Millions
Canton Strategic Holdings Inc   14.18 $ 37.242  Millions$ 2.626  Millions
An2 Therapeutics Inc   14.04 $ 78.387  Millions$ 5.585  Millions
Aclaris Therapeutics Inc   13.97 $ 394.443  Millions$ 28.241  Millions
Pmv Pharmaceuticals Inc   13.85 $ 146.393  Millions$ 10.568  Millions
Generate Biomedicines Inc   13.76 $ 779.456  Millions$ 56.636  Millions
First Tracks Biotherapeutics Inc   13.50 $ 168.018  Millions$ 12.447  Millions
Arrivent Biopharma inc   13.41 $ 373.401  Millions$ 27.844  Millions
Cogent Biosciences Inc   13.36 $ 792.300  Millions$ 59.296  Millions
Aprea Therapeutics Inc   13.33 $ 41.233  Millions$ 3.092  Millions
Polaryx Therapeutics Inc   13.22 $ 11.542  Millions$ 0.873  Millions
Monopar Therapeutics Inc   13.14 $ 52.758  Millions$ 4.016  Millions
Lexicon Pharmaceuticals Inc   12.96 $ 190.610  Millions$ 14.706  Millions
Korro Bio Inc   12.89 $ 162.805  Millions$ 12.628  Millions
Atea Pharmaceuticals Inc   12.89 $ 362.382  Millions$ 28.124  Millions
Oric Pharmaceuticals Inc   12.76 $ 264.761  Millions$ 20.756  Millions
Diamedica Therapeutics Inc   12.42 $ 81.875  Millions$ 6.594  Millions
Vtv Therapeutics Inc   12.35 $ 86.643  Millions$ 7.017  Millions

Date modified: 2026-09-08T22:06:09+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.